Recent Updates
Recently added Catalysts

Stem Cell Educator Therapy

Phase 1

Diabetes Mellitus Type 1 | Monoclonal antibody | Metabolic |Meridian Bioscience Inc|Last Updated: Apr 3, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment13
FDA Designations
No designations recorded
Clinical trial landscape

Stem Cell Educator Therapy · 1 trial · 1 indication

Phase 1 1
NCT02624804A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 DiabetesDiabetes Mellitus Type 1
COMPLETED13 Analytics
PHASE1COMPLETED
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
Diabetes Mellitus Type 1Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Related Adverse Events
12 months

The primary study endpoint will be the occurrence of treatment-related adverse effects. Adverse events that occur during therapy (especially those that necessitate temporary or permanent discontinuation of therapy) and over the 12-month follow-up period will be assessed.

Secondary Endpoints
Number of Patients Unable to Complete Therapy
One week
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Stem Cell Educator TherapyEXPERIMENTALPatients will have apheresis performed and then have their own blood returned to them with the "educated" lymphocytes
Interventions
NameTypeDescription
Stem Cell Educator TherapyBIOLOGICALPatients will receive apheresis and then have their own blood returned to them with the "educated" lymphocytes
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Adult patients \>/=18 years * Must have a diagnosis of type 1 diabetes mellitus based on the 2015 American Diabetes Association criteria for the Clarification and Diagnosis of diabetes * Must have a blood test confirming the presence of at least one autoantibody to pancreatic ...

Countries:United States
Unlock Eligibility Criteria